CTIS2023-504909-37-00Active, not recruitingPhase 1
A clinical trial to evaluate the long-term safety and durability of efficacy of BI 3720931, an inhaled lentiviral vector gene therapy, after single dose administration in a previous clinical trial in people with cystic fibrosis rolled-over from a previous clinical trial with BI 3720931 (LenticlairTM-ON). - 1504-0003
Boehringer Ingelheim International GmbH0 sites27 target enrollmentStarted: January 31, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 27
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •All trial participants who participated in a previous BI sponsored trial with BI 3720931 and have received at least one dose of BI 3720931, or matching placebo, are eligible for participation in extension trial 1504-0003 and should be enrolled., Signed and dated written informed consent in accordance with International Council for Harmonisation (ICH)-Good Clinical Practice (GCP) and local legislation prior to admission to the trial.
Exclusion Criteria
- •There are no exclusion criteria for enrolment into the trial.
Investigators
Similar Trials
Completed
Not Applicable
Clinical study to investigate the long-term safety and efficacy of human cell line recombinant Factor VIII (human-cl rhFVIII) in previously treated patients with severe haemophilia ASevere haemophilia AHaematological DisordersHereditary factor VIII deficiencyISRCTN90038418Octapharma AG (Switzerland)22
Completed
Not Applicable
A long term clinical study for safety evaluation of containing plant-extracts foods. (SME-2021-07)ot applicableJPRN-UMIN000047024Suntory Beverage & Food Limited48
Recruiting
Phase 2
A study of silorimus for pure red cell aplasiaJPRN-jRCTs031230310akazawa Hideyuki5
Recruiting
Phase 3
A phase III/IV clinical study to assess the safety and efficacy of dendritic cell immunotherapy in advanced stage ovarian cancer.CTRI/2010/091/000596Instutute of Cellular Therapies Pvt. Ltd.50
Completed
Unknown
Efficacy trial and long-term safety confirmation test- Efficacy and long-term safety of the test food TK61406 ingested as a single dose, in a double-blind, parallel-group comparison to placebo.A range of individuals from healthy to borderline conditions- Persons with tendency for constipation or diarrhea- Persons classified as normal to 1 degree of obesity- Persons classified with normal to 1 degree of average blood pressureJPRN-jRCT1091220210Tokai Pickling Co.,Ltd. Yasufumi Ohba, Masataka Fujita, Mitsuru Satsukawa, Tetsuhiro Kawamoto, Mika Komura, Shoko Nishio, Tetsuya Iyoda,Hiroshi Ono30